These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 19581216)

  • 21. Candidate genetic modifiers of individual susceptibility to renal cell carcinoma: a study of polymorphic human xenobiotic-metabolizing enzymes.
    Longuemaux S; Deloménie C; Gallou C; Méjean A; Vincent-Viry M; Bouvier R; Droz D; Krishnamoorthy R; Galteau MM; Junien C; Béroud C; Dupret JM
    Cancer Res; 1999 Jun; 59(12):2903-8. PubMed ID: 10383153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biotransformation enzyme polymorphism and pesticide susceptibility.
    Eaton DL
    Neurotoxicology; 2000; 21(1-2):101-11. PubMed ID: 10794390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms.
    Ingelman-Sundberg M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):89-104. PubMed ID: 14574440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Susceptibility to bronchial cancer: an example of genetic-environmental interaction].
    Benhamou S; Bonaïti-Pellié C
    Ann Biol Clin (Paris); 1995; 53(9):507-13. PubMed ID: 8830563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variations in the xenobiotic-metabolizing enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and susceptibility to colorectal cancer among Turkish people.
    Özhan G; Mutur M; Ercan G; Alpertunga B
    Genet Test Mol Biomarkers; 2014 Apr; 18(4):223-8. PubMed ID: 24527758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polymorphism of CYP450 and cancer susceptibility.
    Han XM; Zhou HH
    Acta Pharmacol Sin; 2000 Aug; 21(8):673-9. PubMed ID: 11501173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetics of the major polymorphic metabolizing enzymes.
    Daly AK
    Fundam Clin Pharmacol; 2003 Feb; 17(1):27-41. PubMed ID: 12588628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers.
    Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K
    Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipsychotic agents.
    Murray M
    J Pharm Pharmacol; 2006 Jul; 58(7):871-85. PubMed ID: 16805946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Cytochrome P450 Monooxygenase in Carcinogen and Chemotherapeutic Drug Metabolism.
    Wahlang B; Falkner KC; Cave MC; Prough RA
    Adv Pharmacol; 2015; 74():1-33. PubMed ID: 26233902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metabolism and bioactivation of toxicants in the lung. The in vitro cellular approach.
    Castell JV; Donato MT; Gómez-Lechón MJ
    Exp Toxicol Pathol; 2005 Jul; 57 Suppl 1():189-204. PubMed ID: 16092727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacogenetics-guided dose modifications of antidepressants.
    Seeringer A; Kirchheiner J
    Clin Lab Med; 2008 Dec; 28(4):619-26. PubMed ID: 19059066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Study of the molecular mechanism of human cytochrome P450 and genetic polymorphism of drug oxidative metabolizing enzyme].
    Zhao L; Lou YQ
    Sheng Li Ke Xue Jin Zhan; 1997 Jan; 28(1):35-40. PubMed ID: 10921075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.
    Sikka R; Magauran B; Ulrich A; Shannon M
    Acad Emerg Med; 2005 Dec; 12(12):1227-35. PubMed ID: 16282513
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility--a review.
    Raunio H; Husgafvel-Pursiainen K; Anttila S; Hietanen E; Hirvonen A; Pelkonen O
    Gene; 1995 Jun; 159(1):113-21. PubMed ID: 7607565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children.
    Joseph T; Kusumakumary P; Chacko P; Abraham A; Radhakrishna Pillai M
    Pediatr Blood Cancer; 2004 Oct; 43(5):560-7. PubMed ID: 15382273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer therapy and polymorphisms of cytochromes P450.
    MacLeod SL; Nowell S; Massengill J; Jazieh A; McClure G; Plaxco J; Kadlubar FF; Lan NP
    Clin Chem Lab Med; 2000 Sep; 38(9):883-7. PubMed ID: 11097344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical significance of some genetic polymorphisms of cytochrome P-450: family CYP1 and subfamilies CYP2A, CYP2B and CYP2C].
    Wojtczak A; Skretkowicz J
    Pol Merkur Lekarski; 2009 Mar; 26(153):248-52. PubMed ID: 19388543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of cytochrome P450 enzymes in human nasopharyngeal carcinoma and non-cancerous nasopharynx tissue].
    Jiang JH; Jia WH; Qin HD; Liang H; Pan ZG; Zeng YX
    Ai Zheng; 2004 Jun; 23(6):672-7. PubMed ID: 15191668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.
    Zanger UM; Turpeinen M; Klein K; Schwab M
    Anal Bioanal Chem; 2008 Nov; 392(6):1093-108. PubMed ID: 18695978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.